MarketPulse
T

$TRDA

3 articles found
1 positive
2 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

DMD Pipeline Surge: 75+ Drugs in Development as 70+ Companies Race for Breakthrough Therapies

DelveInsight report reveals robust DMD pipeline with 75+ drugs in development across 70+ companies, including major players advancing gene therapy and dystrophin-targeting treatments.
RHHBYDYNBMRNKROSATOS+4clinical trialsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Holzer & Holzer, Llc

Entrada Therapeutics Under Investigation Over DMD Trial Disappointment

Law firm investigates $TRDA over securities compliance following underwhelming Duchenne muscular dystrophy trial results that triggered stock decline.
TRDAstock declinesecurities investigation
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Entrada Therapeutics Faces Fraud Probe Over Allegedly Misleading Trial Data

Law firm launches shareholder investigation into $TRDA after stock crashes 57% amid disputed clinical trial claims.
TRDAsecurities fraudstock decline